Alkem Laboratories has launched Pertuza, a pertuzumab biosimilar, in India for the treatment of HER2-positive breast cancer. This launch aims to expand access to affordable treatment options meeting global standards. Alkem’s Pertuza is an indigenously developed and manufactured biosimilar, demonstrating equivalence in efficacy and safety. This launch strengthens Alkem’s oncology portfolio and ensures access to critical therapy for thousands of women annually.
Pertuza Launch Overview
Alkem Laboratories Ltd. announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India, designed for the treatment of HER2-positive breast cancer. The launch took place on September 22, 2025.
Key Benefits of Pertuza
Pertuza is an affordable and indigenously-developed biosimilar of pertuzumab. Clinical trials have demonstrated equivalence in efficacy, safety, and immunogenicity compared to the reference product.
Accessibility and Impact
The availability of pertuzumab in India has previously been limited due to cost constraints. By offering an affordable biosimilar, Alkem aims to improve access to HER2-positive breast cancer treatment for a broader patient base.
Executive Perspective
According to Dr. Vikas Gupta, Chief Executive Officer, Alkem, addressing the growing burden of breast cancer requires treatments that are effective, accessible, and affordable. The launch of Pertuza reflects Alkem’s commitment to combining scientific excellence with wider access, potentially benefiting thousands of women annually.
Oncology Portfolio Expansion
Alkem’s growing portfolio of oncology drugs includes products such as cetuximab biosimilar, denosumab biosimilar, bevacizumab biosimilar, and romiplostim biosimilar.
Source: BSE
